On July 4, 2022 Patrys has reported a positive update on the second engineering run for its lead asset PAT-DX1, a critical step for ensuring we can manufacture at commercial scale (Press release, Patrys, JUL 4, 2022, View Source [SID1234616450]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This follows an earlier set-back when the first engineering run for PAT-DX1 was unsuccessful due to low recoveries of drug product during the purification phase.

Patrys CEO and MD, Dr James Campbell, was delighted to share the news today:

"This is an outstanding result, and a tribute to the close working relationship between Patrys and our CDMO. The commercial‑scale manufacture of antibodies is a complex, multi‑dimensional process. The efforts made to understand and remediate the issues with the first engineering run have been both extensive and exhaustive. We are delighted that this has delivered such a successful outcome."